Table 4.
Multivariate analysis
| Parameter | DSS | LRFS | MeFS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| H.R | 95% CI | p-Value | H.R | 95% CI | p-Value | H.R | 95% CI | p-Value | |
| Tumor regression grade | 2.105 | 1.055-4.202 | 0.035* | 2.283 | 1.077-4.853 | 0.031* | 2.427 | 1.221-4.831 | 0.011* |
| CLCA1 expression | 2.172 | 1.022-4.620 | 0.044* | 2.555 | 1.102-5.921 | 0.029* | 2.125 | 1.021-4.421 | 0.044* |
| Vascular invasion | 1.774 | 0.647-4.867 | 0.266 | 1.987 | 0.707-5.587 | 0.193 | - | - | - |
| Post-Tx tumor status (Post-T) | 2.404 | 0.964-5.995 | 0.060 | 1.886 | 0.755-4.711 | 0.175 | 1.988 | 0.843-4.688 | 0.117 |
| Pre-Tx nodal status (Pre-N) | 1.228 | 0.507-2.975 | 0.649 | 1.762 | 0.728-4.263 | 0.209 | - | - | - |
| Pre-Tx tumor status (Pre-T) | 1.286 | 0.543-3.043 | 0.567 | - | - | - | - | - | - |
| Perineurial invasion | - | - | - | 1.317 | 0.273-6.335 | 0.731 | - | - | - |
DSS, disease-specific survival; LRFS, local recurrence-free survival; MeFS, metastasis-free survival; *, statistically significant